Amiodarone-Induced Changes in Lipid Metabolism

Summary

Hypothyroidism is a major cause of secondary hypercholesterolemia. Amiodarone treatment alters both the levels of serum lipids and thyroid hormones. We investigated whether the amiodarone-induced changes in lipid metabolism are related to the changes in thyroid hormone levels. Eighteen patients received amiodarone (31 ± 3 g cumulative dose) for six weeks. Serum triglyceride, total-cholesterol, high density lipoprotein-cholesterol and its subfractions, apolipoproteins B and AI, and plasma post-heparin lipoprotein lipase and hepatic triglyceride lipase activities were determined. Amiodarone treatment caused significant increases in serum total-cholesterol (baseline 4.4 ± 0.21 (SE), 6 weeks 5.12 ± 0.26 mmol/l, P < 0.01), in low density lipoprotein cholesterol (baseline 2.61 ± 0.26, 6 weeks 3.36 ± 0.21 mmol/l, P < 0.05) and in apolipoprotein B (baseline 1.95 ± 0.15, 6 weeks 2.26 ± 0.13 mmol/l, P < 0.01) concentrations. Serum high density lipoprotein and its subfractions, or apolipoprotein AI levels did not change. Plasma post-heparin lipoprotein lipase activity increased (baseline 137 ± 21, 6 weeks 168 ± 21 U/ml, P<0.01) while hepatic triglyceride lipase did not change. Amiodarone also caused an increase in serum thyroxine (baseline 110 ± 8, 6 weeks 136 ± 6 mmol/l, P < 0.05), although values remained in euthyroid range.

In summary, amiodarone therapy increased the concentrations of atherogenic lipoproteins in the serum similar to that seen in hypothyroidism. On the other hand the effect of amiodarone on lipoprotein lipase was opposite to that seen in hypothyroidism. Therefore, amiodarone-induced changes in lipid metabolism cannot be explained solely on the basis of the changes in circulating thyroid hormone levels.

Key words

Amiodarone - Thyroid Hormones - Lipids - Lipoprotein Lipase - Hepatic Lipase